首页 > 科学研究 > 实验血液学研究课题组

> 课题组简介

  本课题组通过密切结合临床,紧扣“淋巴细胞恶性转化分子机制和靶向治疗”的研究主题,运用系统生物学新技术,从基因组学、表观遗传学、代谢组学等多角度,定位、识别与淋巴瘤生物学特性、临床进展、药物敏感性和预后转归密切相关的分子标志。在此基础上,进一步阐明分子标志的生物学作用和调控的重要细胞信号转导途径。筛选针对淋巴瘤关键分子标志及信号途径的特异性靶向治疗药物,积极开展淋巴瘤多靶点、多元化靶向治疗策略的探索和临床转化,提出解决相关临床治疗问题的新方法和新策略,推进临床实践应用。同时,个人和团队互促进,形成一支年轻、富有朝气的淋巴瘤临床转化型研究团队。

> 课题组长:赵维莅


> 代表性论文

1.Wang L, Shi WY, Yang F, Tang W, Gapihan G, Varna M, Shen ZX, Chen SJ, Leboeuf C, Janin A, Zhao WL. Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells. Haematologica. 2011 Jun;96(6):927-31.

2.Shi WY, Xiao D, Wang L, Dong LH, Yan ZX, Shen ZX, Chen SJ, Chen Y, Zhao WL. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis. 2012 Mar 1;3:e275.

3.Dong LH, Cheng S, Zheng Z, Wang L, Shen Y, Shen ZX, Chen SJ, Zhao WL. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma. J Hematol Oncol. 2013 Jul 18;6:53.

4.Yan ZX, Wu LL, Xue K, Zhang QL, Guo Y, Romero M, Leboeuf C, Janin A, Chen SJ, Wang L, Zhao WL. MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma. Leukemia. 2014 Apr;28(4):880-7.

5.Ji MM, Wang L, Zhan Q, Xue W, Zhao Y, Zhao X, Xu PP, Shen Y, Liu H, Janin A, Cheng S, Zhao WL. Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activation. Autophagy. 2015;11(12):2160-71.